Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

Fig. 2

Overall survival of patients in four subgroups. Metastasectomy after an effective sunitinib therapy caused the most favorable overall survival (74.3 months). Median survival of patients with slight progression is longer with dose escalation (58.6 months) than without it (27.9 months), or the outcome of all other patients (17.9 months) (p‹0.001). (Cum – cumulative, OS – overall survival)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us